• 提示：详情请下载说明书。

• 产品描述： Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity. Quisinostat can induce autophagy in neuroblastoma cells

• 靶点： HDAC1:0.11 nM (IC50);HDAC2:0.33 nM (IC50);HDAC4:0.64 nM (IC50);HDAC10:0.46 nM (IC50);HDAC11:0.37 nM (IC50);HDAC3:4.86 nM (IC50);HDAC5:3.69 nM (IC50);HDAC8:4.26 nM (IC50);HDAC9:32.1 nM (IC50);HDAC6:76.8 nM (IC50);HDAC7:119 nM (IC50);Apoptosis; HDAC; Autophagy

• 体内研究：
  Quisinostat (40 mg/kg; p.o.; once daily; for 3 days) acts as a potent HDAC1 inhibitor p21waf1,cip1 ZsGreen tumors in vivo. Quisinostat induces continuous H3 acetylation in tumor tissue in vivo. Quisinostat (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts

• 参考文献：
  1. Arts J, et al. JNJ-26481585, a novel second-generation oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009 Nov 15;15(22):6841-51. 2. Vamsi Krishna Kommalapati, et al. Inhibition of JNJ-26481585-mediated autophagy induces apoptosis via ROS activation and mitochondrial membrane potential disruption in neuroblastoma cells. Mol Cell Biochem. 2020 May;468(1-2):21-34.

• 溶解性： Soluble  in  DMSO

• 保存条件： -20℃

• 配置溶液浓度参考：
  

  	1mg	5mg	10mg
  1 mM	2.535 ml	12.675 ml	25.35 ml
  5 mM	0.507 ml	2.535 ml	5.07 ml
  10 mM	0.254 ml	1.268 ml	2.535 ml
  50 mM	0.051 ml	0.254 ml	0.507 ml

• 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

输入产品批号：

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *